S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$136.20
+1.15 (+0.85%)
(As of 01/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$133.17
$136.32
50-Day Range
$119.87
$149.74
52-Week Range
$117.64
$189.00
Volume
319,436 shs
Average Volume
745,612 shs
Market Capitalization
$8.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Jazz Pharmaceuticals logo

About Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
1,940
Year Founded
2003

Sales & Book Value

Annual Sales
$2.36 billion
Cash Flow
$16.16 per share
Book Value
$65.69 per share

Profitability

Net Income
$238.62 million
Pretax Margin
2.68%

Debt

Price-To-Earnings

Miscellaneous

Free Float
58,827,000
Market Cap
$8.37 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/28/2022
Next Earnings (Estimated)
2/22/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.57 out of 5 stars

Medical Sector

102nd out of 1,417 stocks

Pharmaceutical Preparations Industry

40th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view top-rated stocks.

How has Jazz Pharmaceuticals' stock price been impacted by COVID-19?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JAZZ shares have increased by 26.1% and is now trading at $136.20.
View which stocks have been most impacted by COVID-19
.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Jazz Pharmaceuticals
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analyst estimates of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 5.62% and a positive trailing twelve-month return on equity of 21.43%. During the same period last year, the business earned $3.86 earnings per share.
View Jazz Pharmaceuticals' earnings history
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided earnings per share guidance of $15.100-$15.800 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.520. The company issued revenue guidance of $3.02 billion-$3.10 billion, compared to the consensus revenue estimate of $3.09 billion.

What price target have analysts set for JAZZ?

15 equities research analysts have issued 1 year price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $174.00 to $250.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $209.07 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Bruce C. Cozadd, Chairman & Chief Executive Officer (LinkedIn Profile)
  • Daniel N. Swisher, President
  • Christopher John Tovey, Chief Operating Officer & Executive Vice President
  • Renée D. Galá, Chief Financial Officer & Executive Vice President
  • Robert Iannone, Chief Medical Officer, EVP-Research & Development

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (2.99%), Retirement Systems of Alabama (0.27%), AustralianSuper Pty Ltd (0.25%), Railway Pension Investments Ltd (0.12%), Van ECK Associates Corp (0.12%) and Braun Stacey Associates Inc. (0.08%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, James E Flynn, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals
.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, LSV Asset Management, PGGM Investments, Gulf International Bank UK Ltd, Kendall Capital Management, Hancock Whitney Corp, CFM Wealth Partners LLC, and Kestra Advisory Services LLC. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Kim Sablich, Mark Douglas Smith, and Patricia Carr.
View insider buying and selling activity for Jazz Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Allspring Global Investments Holdings LLC, Van ECK Associates Corp, Stonnington Group LLC, AustralianSuper Pty Ltd, Gateway Investment Advisers LLC, New York State Teachers Retirement System, and GW Henssler & Associates Ltd.. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include James E Flynn, and Seamus Mulligan.
View insider buying and selling activity for Jazz Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $136.20.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $8.37 billion and generates $2.36 billion in revenue each year. The specialty pharmaceutical company earns $238.62 million in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 1,940 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Where are Jazz Pharmaceuticals' headquarters?

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.